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AbstrAct
background: The aim of the study was to investigate the safety of combining preoperative stereotactic body radiotherapy 
(sBrT) with robotic radical prostatectomy (rp) for high risk prostate cancer (hrcap). Many patients with hrcap will require 
adjuvant or salvage radiotherapy after rp. The addition of preoperative sBrT before rp may spare patients from subsequent 
prolonged courses of rT.
Materials and methods: eligible patients had NccN hrcap and received a total of 25 Gy or 30 Gy in five daily fractions of 
sBrT to the prostate and seminal vesicles followed by robotic rp with pelvic lymphadenectomy 31-45 days later. The primary 
endpoint was prevalence of acute genitourinary (GU) and gastrointestinal (GI) toxicity. secondary endpoints were patient-
reported quality of life (QOL) and biochemical recurrence (Bcr).
results: Three patients received preoperative sBrT to 25 Gy and four received 30 Gy. Median follow-up was 18 months. high-
est toxicity was grade 2 and 3 in six (85.7%) and one (14.3%) patients, respectively. all patients developed grade 2 erectile 
dysfunction and 4 of 7 (57%) developed grade 2 urinary incontinence (UI) within a month after surgery. One patient devel-
oped acute grade 3 UI, but there was no grade ≥ 4 toxicity. One patient experienced acute grade 2 hemorrhoidal bleeding. 
On QOL, acute GU complaints were common and peaked within 3 months. Bowel symptoms were mild. Two patients with 
pN+ experienced Bcr.
conclusions: preoperative sBrT before robotic rp in hrcap is feasible and safe.  The severity of acute GU toxicity with preop-
erative sBrT may be worse than rp alone, while bowel toxicity was mild.
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Much attention has been given to the emergence 
of stereotactic body radiotherapy (SBRT) as a stan-
dard therapy of lung [1, 2] and liver lesions [3, 4]. 
Considerable literature has emerged regarding de-
finitive therapy of prostate cancer with SBRT [5–8], 
typically consisting of five fractions of 7.25–8.00 
Gy/fraction delivered either daily or every other 
day. Prior to 2020, this technique involving ul-
tra-hypofractionation was recommended in the 
National Comprehensive Cancer Network (NCCN) 
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Guidelines on prostate cancer for patients with very 
low risk to favorable intermediate risk disease be-
cause of the preponderance of data supporting the 
addition of hormonal therapy to conventionally 
fractionated radiotherapy for unfavorable inter-
mediate to high-risk disease [9, 10]. Beginning in 
2020, the NCCN Guidelines recommend defini-
tive SBRT consisting of 7.25–8.00 Gy × 5 fractions 
as a treatment option for high risk and very high 
risk prostate cancer. However, preoperative SBRT 
remains investigational.
Recently, the use of SBRT preoperatively has 
been described in small trials in the breast [11] and 
pancreatic [12] cancer literature. This technique is 
attractive for several reasons: (a) it allows for tis-
sue collection both before and after a significant 
local intervention; (b) it could potentially serve to 
remove the need for far longer courses of adjuvant 
[13–15] or salvage [16] RT which may be subse-
quently required in up to 54% of patients with ad-
verse pathologic features.  However, the surgical 
safety of such a technique is unknown. 
The aim of the study was to evaluate the safety 
and feasibility of preoperative SBRT followed by 
robotic radical prostatectomy (RP) for patients with 
high risk adenocarcinoma of the prostate (HRCaP).
Materials and methods
This was a single institution phase I, dose-escala-
tion trial using a traditional 3 + 3 design. The study 
was approved by the H. Lee Moffitt Cancer Center 
and Research Institute’s institutional review board 
and registered (clinicaltrials.gov NCT02572284); all 
participants gave their informed consent. Patients 
were staged and assessed for eligibility based on 
their pre-treatment clinical characteristics rather 
than their pathological characteristics. They were 
eligible if they had: 1) Gleason score 4 + 4 or 4 + 5 
adenocarcinoma on prostate biopsy; 2) ≤ 4 cores 
with grade group (GG) 4–5 adenocarcinoma; and 
3) ≤ cT3aN0M0 stage IIIC disease. Patients under-
went pre-study bone scans and pelvic imaging to 
rule out obvious metastases.  Magnetic resonance 
imaging of the prostate/pelvis was not required. All 
procedures and pathology review were performed 
at the Moffitt Cancer Center. 
Prevalence of acute toxicity according to Com-
mon Terminology Criteria for Adverse Events (CT-
CAE v4 form) was the primary endpoint. Second-
ary endpoints included patient reported quality 
of life (QOL) measures on the American Urology 
Association Symptom Index (AUA) and Expanded 
Prostate Cancer Index Composite (EPIC) patient 
questionnaires, as well as biochemical recurrence 
(BcR). QOL surveys and toxicity assessments 
were recorded at baseline, one month after SBRT, 
monthly after RP for three months, then every three 
months thereafter.
SBRT was delivered in five fractions over one 
week and prescribed to the planning target volume 
(PTV) with RP performed 31–45 days post-RT, 
depending on operating room availability. All pa-
tients had 3–4 gold fiducial seeds placed in the 
prostate under transrectal ultrasound guidance 
prior to treatment planning by commuted tomog-
raphy (CT). SBRT dosimetry constraints are out-
lined in the Appendix. The lowest daily dose used 
was 5.00 Gy per fraction delivered to the PTV 
based on published data: 5.00 Gy × 5 followed by 
surgery has been shown to be safe in rectal cancer 
[17, 18]. Three patients were treated at this dose 
level. If one (i.e., ≥ 33%) of the three planned pa-
tients experienced a dose-limiting toxicity (DLT), 
defined as CTCAEv4 grade ≥ 3 toxicity attributable 
to preoperative SBRT alone or preoperative SBRT 
and surgery, then three additional patients would 
have been treated at this level with dose escalation 
only if there were no additional DLT. No DLT was 
noted at a daily dose of 5.00 Gy, so the dose was 
escalated to 6.00 Gy for the next three patients. 
While no DLT was observed at the 6.00 Gy dose, 
there were reports of such toxicities at the 7.00 Gy 
dose in patients being treated on a similar trial at 
another institution (Daniel Spratt, University of 
Michigan, unpublished data), so one additional 
patient was treated at 6.00 Gy and the trial was 
closed.
 Patients with positive surgical margin (PSM), 
seminal vesicle invasion (SVI), or extraprostatic 
extension (EPE) on the prostatectomy specimen 
were followed without additional radiotherapy to 
the prostate bed since they had already received the 
maximal radiotherapy dose. For the purpose of the 
protocol, we considered this would be analogous to 
a situation where a patient receives postoperative 
radiotherapy to the prostatectomy bed for disease 
progression after PSM, SVI, or EPE.  Postopera-
tive diagnostic prostate specific antigen (PSA) was 
monitored every 3–6 months. 
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If a patient developed recurrent prostate can-
cer, defined as an increase in PSA ≥ 0.2 ng/mL 
post-prostatectomy [19] , he was not eligible for 
further local RT, although patients were eligible for 
radiotherapy to sites other than the prostatectomy 
bed, e.g., distant metastases. Patients who devel-
oped recurrent prostate cancer after preoperative 
SBRT and RP were evaluated by a medical oncolo-




Baseline characteristics are detailed in Table 1. 
The median time to RP after completion of SBRT 
was 35 days (range 31–45). Post-operative GS 
ranged from 7–9, and five patients (71.4%) had GS 
downgraded from 8 on prostate biopsy to 7 on RP. 
The median pre-treatment PSA was 8.40 ng/mL 
(range 5.93–51.70). Two patients had 2–3 high-risk 
features: one had GG 5 and a preoperative PSA >20 
ng/mL; another had GG 5, a preoperative PSA > 20 
ng/mL and cT3a disease. No patient had features 
of NCCN very high-risk disease. Two patients had 
pathologically confirmed positive pelvic lymph 
nodes. Surgical margins were positive in three of 
seven cases (43%).
physician-reported adverse events
Highest grade toxicity was grade 2 and 3 in 
six (85.7%) and one (14.3%) patients, respective-
ly. Prevalence of urinary incontinence (1A) and 
overall GU toxicity (1B) are summarized in Fig-
ure 1. Adverse events occurring in the post-SBRT 
period (0-1 month) were mild, most commonly 
grade 1 cystitis. There was no urinary inconti-
nence in the post-SBRT period. All seven patients 
experienced at least one grade 2 GU event in the 
acute post-RP period (0–1 month), most com-
monly erectile dysfunction (100%). Six patients 
experienced urinary incontinence within the 
2–5-month period following RP, including four 
patients with grade 2 and one with grade 3, which 
was the only grade ≥ 3 GU adverse event. Two 
patients experienced acute GI adverse events, 
including one grade 1 and one grade 2 hemor-
rhoidal bleed, both within 0-1 month following 
RP. Two patients (28.5%) experienced late ad-
verse events within the study period, including 
one grade 1 erectile dysfunction and one grade 
1 urinary incontinence at 5 months, and grade 2 
erectile dysfunction at 8 months. All GI and GU 
toxicities for each individual patient can be seen 
in the Supplementary Table S1.
patient-reported quality of life
Patient-reported QOL scores were determined 
by EPIC and AUA questionnaires at follow-up 
visits. Patient reported QOL scores closely mir-
rored physician assessments of toxicity. Overall 
AUA score rose from baseline starting within one 
month of completing SBRT and peaking within 
2–5 months following RP (Fig. 2). Complaints of 
urinary leakage rose from baseline 0–1 months 
post-RP and were persistent through 6–9 months 
(Fig. 3A). Total AUA scores correlated closely with 
the EPIC overall urinary score, which rose from 
baseline 0–1 months post-RP and peaked between 
2–5 months (Fig. 3B). Bowel complaints were mild 
















PSABiopsy RP Pre-op Post-op Clinical Pathologic
1** 62 25 31 4 + 5 5 + 4 25,33 0,59 cT3a ypT3bN1 (+) 34 1,25
2 54 25 36 4 + 4 3 + 4 7,91 < 0.02 cT1c ypT3aN0 (+) 26 < 0.02
3 58 25 32 4 + 4 4 + 3 t5 8,4 < 0.02 cT1c ypT2cN0 (–) 10 < 0.02
4 64 30 31 4 + 4 4 + 3 t5 8,66 < 0.02 cT1c ypT3aN0 (+) 24 < 0.02
5 64 30 35 4 + 4 3 + 4 5,93 < 0.02 cT2b ypT2aN0 (–) 17 < 0.02
6 58 30 36 4 + 4 3 + 4 5,94 < 0.02 cT2a ypT3aN0 (–) 18 < 0.02 
7** 66 30 45 4 + 5 4 + 5 51,7 3,69 cT1c ypT3aN1 (–) 12 < 0.02
F/U — follow-up; m — months; sBrT — stereotactic body radiotherapy; rp — radical prostatectomy; psa — prostate specific antigen; **patient experienced 
biochemical recurrence
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and peaked within one month following RP, and 
then recovered to baseline (data not shown).
Oncologic outcomes
Two patients developed BcR (Tab. 1, patient 1 and 
patient 7).  Each patient who experienced BcR had 
GG 5 on prostate biopsy, pre-treatment PSA > 25 
ng/mL with detectable post-operative PSA, and 
pathologically positive pelvic lymph nodes. Patient 
1 was treated to the 25 Gy dose level, had ypT3b 
disease with PSM, and post-operative PSA of 0.59 
which rose to 0.78. Patient 7 was treated to the 
30 Gy dose level, had ypT3a disease with negative 
surgical margins, and post-operative PSA of 3.69 
which rose to 7.15. Neither had evidence of distant 
metastasis on CT scans of the chest, abdomen and 
pelvis, or on radionuclide bone scans. Both were 
given ADT with leuprolide and bicalutamide after 
multi-disciplinary evaluation and achieved an un-
detectable PSA.
Discussion
The present study reports short-term results of 
a phase I dose-escalation protocol investigating the 
safety of preoperative SBRT to 25 or 30 Gy in 5 daily 
fractions consisting of 5–6 Gy perfraction, followed 
by robotic RP with pelvic lymph node dissection for 
HRCaP.  With a median follow-up of 18 months, 
all seven patients experienced some degree of mild 
to moderate acute post-operative GU or GI tox-
icity, while two patients (28.5%) experienced late 
grade 1 or grade 2 events. Two patients, both with 
pre-treatment PSA > 20 ng/mL, GG 5 and pN+ 
disease, experienced BcR. The moderate toxicity 
profile suggests that this combined modality treat-
ment paradigm is feasible and safe for patients with 
HRCaP. 
There is increasing interest in combining pre-
operative RT followed by RP for high-risk disease. 





































































Figure 2. Mean (± standard error), minimum, and 
maximum total aUa scores
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an approach are currently active or completed. Re-
cently published short-term results of a similar trial 
of 11 patients treated with preoperative SBRT to 24 
Gy in three fractions over five days to the prostate 
and seminal vesicles followed by RP showed the 
highest GU toxicity of grade 2 and grade 3 in four 
(36.4%) and two (18.2%) patients, respectively [20]. 
The authors reported that one patient had grade 2 
and two patients had grade 3 urinary incontinence, 
and at 12 months, the only grade ≥ 2 toxicity was 
incontinence. Another similarly designed trial of 
preoperative RT to the prostate alone to 25 Gy in 
five daily fractions in 15 patients with favorable 
intermediate to high-risk disease reported that 40% 
developed late grade 3 vesicourethral anastomotic 
stricture, urinary incontinence, or both [21, 22]. 
While that trial has considerably longer follow-up 
of 12.2 years, 11 of the 12 late GU events occurred 
within two years. Differences in treatment tech-
nique may account for the increased rate of late 
grade 3 adverse events compared to the present 
study, as 14 of 15 patients in the Glicksman trial 
were treated with three-dimensional-conformal 
RT techniques, which has been associated with in-
creased toxicity compared to modern techniques 
such as SBRT [23]. Further, the median time to 
RP following RT was just six days, compared to 
14 days in the study by Parikh et al. and 35 days 
in the present study. It is possible that the interval 
between neoadjuvant RT and surgery may affect 
the risk for complications, as has been shown for 
rectal cancer [24]. Another published trial in the 
preoperative setting included twelve men treated 
with preoperative RT to a max dose of 54 Gy to the 
prostate and seminal vesicles and 45 Gy to the pel-
vic lymph nodes in 1.8 Gy per fraction. The authors 
reported moderate GU toxicity, with late grade ≥ 2 
events in 42%, including 17% with symptomatic 
urinary stricture requiring dilation, similar to our 
results, allowing for differences in sample size [25]. 
While small, the present results add to the grow-
ing literature that combined modality treatment 
with preoperative SBRT followed by RP with pelvic 
lymph node dissection is feasible and safe but may 
result in increased severity of urinary incontinence 
compared to RP alone.
The risk of GI or GU adverse events for prostate 
cancer patients treated with preoperative RT ap-
pears to be similar to patients treated with post-op-
erative RT in phase III clinical trials. EORTC 22911 
reported that the rate of late ≥ 2 GU toxicity was 
21.3% in patients treated with post-operative RT, 
and 70.8% had late toxicity of any kind or grade 
[13]. Hackman et al. reported that nearly all pa-
tients treated with post-operative RT experienced 
late toxicity, including 91% with grade 2 and 56% 
with grade 3, primarily urinary disorders and erec-
tile dysfunction [14]. The ARO 96-02 trial is an 
outlier compared to similar trials, as only one out 
of 148 patients treated with adjuvant RT had grade 
3 toxicity [26]. In the SWOG 8794 study, QOL 
scores were initially worse for patients treated in 
Figure 3. A. Mean (± standard error), minimum, and maximum epIc frequency of urine leakage scores; b. Mean (± standard 
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the RP plus adjuvant RT arm compared to the RP 
alone arm. However, after two years the patients 
treated with adjuvant RT had superior QOL [15, 
27]. In these phase III trials of adjuvant RT, the 
rate of urinary toxicity was higher for RP plus RT 
than for RP alone, though adjuvant RT was not al-
ways associated with worse GI toxicity. Given that 
cause-specific survival after EBRT plus ADT or RP 
alone remains high, and many patients with HR-
CaP treated with RP will not require adjuvant or 
salvage therapy [28–30], a high safety threshold is 
needed for a combined modality approach.
Two patients in this trial were found to have 
pathologically positive lymph nodes, raising the 
question of optimal management for pN+ disease 
in this setting. Retrospective data suggest the ad-
dition of adjuvant pelvic RT to ADT may improve 
outcomes in selected patients with pN+ disease af-
ter RP [31–34]. In the current protocol, the role 
of ADT was left to provider discretion, while RT 
was delivered preoperatively to the prostate and 
seminal vesicles only without treatment of regional 
lymphatics. In the study reported by Glicksman et 
al., two patients were found to have regional nodal 
disease after RP, and they were treated with ADT 
without additional radiotherapy [21, 22]. The two 
patients in the study by Parikh et al. who had patho-
logically positive pelvic lymph nodes were treated 
more aggressively with ADT and additional RT to 
the pelvic lymph nodes based upon multi-disciplin-
ary recommendation [20]. The addition of adjuvant 
RT targeted at lymph nodes should be carefully 
considered and determined in multi-disciplinary 
fashion, as the population most likely to benefit has 
not been defined and carries the risk for signifi-
cant increase in toxicity. In the absence of positive 
lymph nodes or biochemical recurrence, combin-
ing preoperative SBRT with RP may allow patients 
to avoid ADT altogether.
A theoretical advantage of preoperative SBRT 
is that it might ablate extra-prostatic microscopic 
disease, which could improve the ability to achieve 
negative surgical margins with current nerve-spar-
ing surgical techniques. The reported rates of posi-
tive margins following RP vary substantially from 
11–48%, but laparoscopic robot-assisted RP has 
been shown to decrease the rate compared to con-
ventional laparoscopic RP [35]. Glicksman et al. re-
ported that seven of 14 (50%) patients had positive 
margins after preoperative RT, which the authors 
felt was related to the short timeframe between RT 
and surgery [21, 22]. However, the rate of positive 
surgical margin was 43% in the present study, de-
spite significantly longer interval between RT and 
surgery. Thus, preoperative SBRT may not signifi-
cantly alter the rates of positive surgical margin.
A further theoretical advantage for the preop-
erative delivery of SBRT is that it allows for tis-
sue examination afterwards, which could improve 
prognostication and therapeutic decision making, 
as has been extensively demonstrated in the breast 
cancer literature for neoadjuvant chemotherapy 
[36]. Multiple studies of neoadjuvant hormonal or 
systemic therapy have demonstrated the rarity of 
pathologic complete response in high risk pros-
tate cancer (reviewed in [37]). While we did not 
evaluate specifically for pathologic response, 71% 
of patients in our trial had a downgraded GS from 
8 on prostate biopsy to 7 on RP. This phenomenon 
has been previously described [38, 39] and has been 
associated with improved outcomes [40]. Tissue 
evaluation after RT can also provide insight into 
tumor biology and the effects of RT delivery. The 
prostate cancer tissue obtained from RP of patients 
who received preoperative RT showed evidence of 
long-term growth arrest via induction of p53 path-
ways [22]. Similarly, evaluation of prostate tumor 
samples for the presence of infiltrating immune 
cells after preoperative SBRT showed infiltration 
of myeloid, rather than lymphoid immune pop-
ulations [41]. In the burgeoning era of precision 
medicine, continued study of tumor response to 
neoadjuvant therapy should remain a priority, as 
such information may be useful to further optimize 
individual therapy in prostate cancer.
conclusion
The present study demonstrates preoperative 
SBRT followed by robotic RP with pelvic lymph 
node dissection for HRCaP is feasible and safe. 
Interpretation of results from this trial is limited by 
the small sample size and short median follow-up 
of 18 months. Longer follow-up is required to eval-
uate the incidence of late toxicity, while subsequent 
studies are required to determine the efficacy in 
comparison to established therapeutic options and 
to define the patient population, if any, who would 
most benefit from this combined modality treat-
ment regimen.
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